July 28, 2026

Using Competitive Intelligence Across the Pharma Value Chain

How Competitive Intelligence informs strategic decision-making from discovery to commercialisation, with real-world examples.

Drug development is built on decisions. Which therapeutic area should we invest in? How differentiated is our asset? Which competitors matter most? When is the right time to enter the market? 

The answers rarely come from a single source. Clinical trials, scientific publications, regulatory decisions, conference presentations and competitor announcements each provide part of the picture. The challenge is interpreting how those developments fit together and what they mean for future strategy.

Competitive Intelligence connects those signals. By combining structured monitoring with scientific and commercial analysis, it helps organisations understand the competitive environment and make informed decisions throughout the pharmaceutical value chain.

The following sections explore how the questions, priorities and intelligence requirements evolve from discovery through to commercialisation, illustrated with real-world examples.

1. Discovery and Early Development

Before significant investment is made, companies need confidence that they are pursuing the right opportunity. That means understanding where innovation is happening, how crowded the field has become and whether an asset is sufficiently differentiated. Some of the questions explored at this stage include:
  • Which companies are investing in this therapeutic area?
  • Which technologies are emerging?
  • Where are the unmet opportunities?
  • Which indications offer the strongest strategic fit?

Building that picture often involves therapy area landscape mapping, early pipeline intelligence, target validation, platform benchmarking and market opportunity assessments. Together, they provide the evidence needed to prioritise indications and shape portfolio strategy.

Example in practice

One project involved supporting a drug delivery company looking to identify the indications best suited to its technology platform. Competitor profiling, technology benchmarking, market opportunity assessment and Target Product Profile (TPP) development were combined to compare multiple opportunities. The outcome was a prioritised view of where the platform offered the strongest strategic fit. Learn more.

2. Clinical Development

As programmes move into clinical development, the competitive landscape becomes more dynamic. New trial initiations, protocol amendments, conference presentations, and clinical readouts continually reshape expectations. Rather than monitoring individual events, the focus shifts to interpretating what those developments reveal about competitor strategy. Typical questions include:
  • How are competitors designing their studies?
  • Which clinical endpoints are becoming the benchmark?
  • Which assets are approaching major milestones?
  • What do recent data readouts suggest about future positioning?
Clinical trial intelligence, company profiling, conference coverage and competitive readout analysis help interpret emerging evidence within the wider competitive landscape.

Example in practice

A neurology company wanted a clearer understanding of the acute psychosis segment in schizophrenia. The assessment combined competitor profiling, conference intelligence and pipeline analysis to evaluate development strategies, expected launch timelines and the likelihood of success across competing assets. The findings provided a stronger evidence base for future development planning. Learn more.

3. Regulatory and Approval

Regulatory activity influences far more than approval dates. A label expansion, reimbursement decision or competitor approval can quickly change market expectations and launch planning. Viewed in isolation, these developments are useful. Viewed together, they reveal how the market dynamics is likely to evolve. Questions typically include: 

  • When are competitor approvals expected?
  • Which products are likely to reach the market first?
  • How are labels evolving?
  • What could upcoming HTA decisions mean for market access?

Answering those questions requires regulatory monitoring alongside approval tracking, label and indication benchmarking, patent intelligence and policy monitoring.

Example in practice

One pharmaceutical company wanted to estimate approval timelines for competitor therapies in obesity and weight-related complications. Clinical trial intelligence was combined with regulatory pathway analysis to model realistic approval scenarios and compare competitor timelines against the client’s own development programme. The full case study explains how this analysis informed regulatory planning.

4. Launch, Commercialisation and Lifecycle Management

Competitive Intelligence does not stop once a product reaches the market. Competitors continue generating clinical evidence, refining their positioning, expanding indications, and responding to changing market conditions. Keeping pace with those developments is just as important as understanding them before launch.
  • How are competitors positioning their brands?
  • Which messages are reaching healthcare professionals?
  • What strategic moves could reshape the market?
  • Which developments should be treated as early warning signals?
Commercial monitoring, promotional claims analysis, KOL mapping, conference coverage, social media intelligence, and ongoing competitor tracking provide a continuous view of the market and help identify emerging opportunities and early warning signals.

Example in practice

A retinal health company required continuous monitoring across competitor activity, regulatory developments, conference insights and commercial launches. The programme brough together ongoing monitoring with strategic recommendations, opportunity and risk assessments and early warning signals, providing a continuous view of the competitive landscape as it evolved. For more detail on the approach and outcomes, read the full case study.

Conclusion

Competitive Intelligence is sometimes viewed as a launch activity or a response to competitor news. In practice, it begins much earlier.

The questions change as products move through the pharmaceutical value chain, but each stage contributes to a broader understanding of the market and competitive landscape. Connecting those insights over time provides a stronger foundation for portfolio strategy, clinical development, regulatory planning and commercial decision-making.

At m360 Research, we partner with life sciences organisations across every stage of the pharmaceutical value chain. Whether supporting an early landscape assessment, conference coverage, competitor profiling or a long-term monitoring programme, our focus remains the same: delivering evidence-based intelligence that helps clients make informed strategic decisions.

Partner With Us

If you’ve been searching for solid partnerships to drive innovation, then look no further.

Let's get started

Latest Articles